o	Management to host a Capital Markets Day at Thompson Central Park New York on
September 20, 2023 from 10:00 a.m.-1.30 p.m. ET / 4:00-7:30 p.m. CET.

o	Highlights to be covered include recent developments within our pipeline of
innovative cancer vaccines, with a spotlight on the differentiating factors of
our Nykode technology platform and our leading assets, VB10.16 (wholly owned)
and VB10.NEO (in collaboration with Genentech).

o	Guest speaker Dr. Bradley Monk, VP and Member of Board of Directors
GOG-Foundation, will provide an insight in the treatment landscape for cervical
cancer and perspectives on VB10.16.

o	The event is a live, virtual event with the possibility for physical
attendance. The event can be followed via a live video webcast with access to
the presentation slides from the Company's website.

Oslo, Norway, September 7, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, invites to a Capital Markets Day for
analyst and investors at the Thompson Central Park New York on September 20,
2023 from 10:00 a.m.-1:30 p.m. ET / 4:00-7:30 p.m. CET. The event will be hosted
as a live, virtual event, with the possibility for physical attendance. The
event can be followed via a live video webcast with access to the presentation
slides from the Company's website. 

The Capital Markets Day will feature Nykode's Executive Management Team who will
provide an update on the development and future potential of Nykode's business,
as well as a deep dive into our strategic vision. During this event, we will
unveil recent developments within our pipeline of innovative cancer vaccines
with a spotlight on the differentiating factors of our Nykode technology
platform and our leading assets, VB10.16 (wholly owned) and VB10.NEO (in
collaboration with Genentech, a member of the Roche Group).

Our agenda also features a presentation by Dr. Bradley Monk, VP and Member of
the Board of Directors of the GOG-Foundation, who will provide insight in the
ever-evolving treatment landscape for cervical cancer and perspectives on
VB10.16.

For a comprehensive overview of our agenda and additional details, please refer
to the full schedule attached hereto. 

The live and archived webcast of the presentation can be accessed in the
Investors section of the Company's website:
https://nykode.com/investors/financial-reports-and-presentations

Physical attendance requires registration. To register for the physical event,
please send an email to Alexandra Deschner, Head of IR, e-mail: ir@nykode.com by
Thursday September 14, 2023. 

Nykode will also host a similar Capital Markets Day in Oslo, Norway on September
27, 2023. Details and agenda for this event will follow in due course. 


Event details:
Date and time: September 20, 2023 from 10:00 a.m.-1:30 p.m. ET / 4:00 p.m.-7:30
p.m. CET
Location: Thompson Central Park New York, 119 West 56th Street, New York
Webcast and replay:
https://nykode.com/investors/financial-reports-and-presentations
Presentation material:
https://nykode.com/investors/financial-reports-and-presentations


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer, infectious diseases and autoimmune diseases. Nykode's modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which have
been shown to induce broad, strong and long-lasting antigen specific immune
responses and elicit efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive efficacy and safety results from its Phase 2 trial for the
treatment of cervical cancer